Introducing BCOP Sprint
NEW! Timely BCOP Learning with Your Time In Mind
Sometimes all you have is 30 minutes to spare. With BCOP Sprint, that's all the time you need.
HOPA introduces BCOP Sprint, new education programming where you can earn BCOP CEs and take a deep dive into the latest developments in hem/onc pharmacy – all in just 30 minutes. Throughout the year, BCOP Sprint's 30-minute sessions will alternate between hyper-specialized and late-breaking hematology and solid malignancy topics, "drilling down" to real-time information.
BCOP Spring 2026 Session 1 – Now On-Demand
"UnPACCing Treatment of Uncommon EGFR Mutations"
- Availability: Through Sept. 23, 2027
- Cost: $20 for HOPA members, $26 for non-members
- BCOP Credits: 0.5 ACPE/BCOP credits
Course Description
This presentation will provide an overview of uncommon EGFR mutations in non-small cell lung cancer, focusing on PACC mutations. We will review a structure-based classification framework for EGFR mutations and how this influences drug binding, treatment sensitivity, and therapeutic decision-making. Participants will review current guidelines as well as emerging clinical evidence for the first line treatment of EGFR PACC mutations, including novel agents. Real world data, clinical trial data, and a case example will be used to highlight practical considerations in treatment selection and unmet needs in this patient population.
Learning Objectives
- Outline how structure-based classification of EGFR mutations can impact treatment selection for patients
- Explain the treatment landscape for first line treatment options in patients with EGFR PACC mutations, and including emerging and novel treatment options
Presenter
Amanda S. Cass is a clinical pharmacist specialist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. In her role, she provides expert pharmaceutical care within the Thoracic Oncology Clinic, focusing on the management of lung cancers and contributing to the advancement of oncology pharmacy practice.
She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center and became a Board Certified Oncology Specialist in 2019.
Beyond her clinical responsibilities, Dr. Cass contributes to the oncology pharmacy community through education and research. She serves as a preceptor for the Outpatient Thoracic Oncology Rotation at VUMC, mentoring pharmacy residents and students. Her scholarly work includes publications on targeted therapies used to treat NSCLC and managing their adverse effects, such as strategies to address diarrhea associated with EGFR tyrosine kinase inhibitors. Additionally, she has participated in continuing education programs, discussing topics like DLL3-targeting bispecific T-cell engager (BiTE) therapy in SCLC, molecular mutations in NSCLC, and use of immunotherapy in NSCLC.
BCOP Sprint 2026 Session 2
"Cancer Therapy Considerations in Transgender and Gender Diverse Patients Receiving Gender Affirming Hormonal Therapy"
- BCOP Credits: 0.5 ACPE/BCOP credits
- Credit Claim Availability: Through Oct. 26, 2026
Course Description
Join us as we embark on an interview-style conversation examining cancer therapy dosing considerations in transgender and gender diverse patients receiving continuous gender affirming hormonal therapy (GAHT). This discussion will include real world examples and clinical pearls to provide both clinical and cultural context for oncology pharmacists.
Learning Objectives
- Describe laboratory value changes that can occur while patients are receiving continuous gender affirming hormonal therapy (GAHT)
- Apply appropriate calculations for dosing antineoplastic agents in transgender or gender diverse patients (TGD)
There will be 0.5 ACPE and BCOP credits available for this session.
Session 2 is available to attendees of the live webinar through October 26, 2026. On-demand access will be available starting October 27, 2026.
Presenters
Christy S. Harris, PharmD, BCOP, FHOPA, is an Associate Professor of Pharmacy Practice at Massachusetts College of Pharmacy & Health Sciences in Boston with a practice site at Dana-Farber Cancer Institute. Dr. Harris is a graduate of the University of Tennessee where she received her Bachelor of Science and Doctor of Pharmacy degrees. She completed a Clinical Pharmacy residency at the University of Tennessee Medical Center in Knoxville and an Oncology Pharmacy residency at the Medical University of South Carolina in Charleston. She is board certified in Oncology and is a Fellow of the Hematology/Oncology Pharmacy Association. She teaches oncology subjects to pharmacy students in the classroom and caring for the patient with cancer in the clinical setting. At her practice site, she works with providers within the Center for Soft Tissue and Bone Sarcomas and follows patients treated in the Integrative Medicine clinic, assessing supplements for safety during cancer therapy. Other interests in her practice include early-phrase clinical trials, clinical research, and the Adolescent and Young Adult population.
Dr. Leiva (pronouns he/him) is a Board Certified Oncology Pharmacist and an Advanced Practice Pharmacist and educator. Dr. Leiva received his PharmD at Loma Linda University School of Pharmacy in 2010. Prior to pharmacy school, Dr. Leiva completed a B.S. in Microbiology and was an NIH Fellow in the RISE program while pursuing an M.S. in Microbiology. In addition to practicing in several states, he has taught at pharmacy schools on both coasts. Dr. Leiva is a preceptor to pharmacy students, residents, and fellows. Dr. Leiva serves his community as an intermittent Federal Disaster Response Official Pharmacist for the Department of Health and Human Services, where he may be deployed to local, regional, national, and international disasters. Most recently, he was deployed for Hurricane Helene and the So Cal Fires. Dr. Leiva is an Associate Professor of Pharmacy Practice at West Coast University School of Pharmacy.
